ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.691,32
0,05%
S&P 500
5.267,84
-0,74%
Dow Jones
39.065,26
-1,53%
Euro vs US Dollar
1,08175
-0,07%
Bitcoin
67.333,11
-2,56%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Tango Therapeutics Inc (TNGX)

  7. Tango Therapeutics Inc (TNGX) News

TNGX

Tango Therapeutics (TNGX)

Tango Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:TNGX
DatumZeitQuelleÜberschriftSymbolFirma
23/05/202415h18PR Newswire (US)Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical programNASDAQ:TNGXTango Therapeutics Inc
23/05/202413h18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
23/05/202413h00Business WireTango Therapeutics Announces Discontinuation of TNG348 ProgramNASDAQ:TNGXTango Therapeutics Inc
08/05/202413h21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNGXTango Therapeutics Inc
08/05/202413h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
08/05/202413h00Business WireTango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
01/04/202422h48Business WireTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TNGXTango Therapeutics Inc
18/03/202412h00Business WireTango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
06/03/202413h00Business WireTango Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:TNGXTango Therapeutics Inc
05/03/202422h47GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:TNGXTango Therapeutics Inc
09/02/202403h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
09/02/202403h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
07/02/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
05/02/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
05/02/202422h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
31/01/202413h00GlobeNewswire Inc.Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceNASDAQ:TNGXTango Therapeutics Inc
05/01/202422h05GlobeNewswire Inc.Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TNGXTango Therapeutics Inc
04/01/202408h47PR Newswire (US)Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical studyNASDAQ:TNGXTango Therapeutics Inc
03/01/202413h00GlobeNewswire Inc.Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ CancersNASDAQ:TNGXTango Therapeutics Inc
13/11/202313h00GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual MeetingNASDAQ:TNGXTango Therapeutics Inc
08/11/202313h29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNGXTango Therapeutics Inc
08/11/202313h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
08/11/202313h00GlobeNewswire Inc.Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
07/11/202313h00GlobeNewswire Inc.Tango Therapeutics to Present at the Jefferies London Healthcare ConferenceNASDAQ:TNGXTango Therapeutics Inc
02/11/202321h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
18/10/202323h23Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:TNGXTango Therapeutics Inc
18/09/202313h00GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:TNGXTango Therapeutics Inc
12/09/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TNGXTango Therapeutics Inc
06/09/202313h00GlobeNewswire Inc.Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ CancersNASDAQ:TNGXTango Therapeutics Inc
05/09/202313h00GlobeNewswire Inc.Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:TNGXTango Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TNGX

Kürzlich von Ihnen besucht

TG
432
Arbor Metals
NYSE
KO
Coca Cola
TG
BAS
BASF
NASDAQ
TSLA
Tesla
TG
CBK
Commerzbank
TG
LHA
Deutsche Lufthansa
NASDAQ
MSFT
Microsoft
TG
D7G
Nel ASA
NYSE
XOM
Exxon Mobil
TG
RHM
Rheinmetall
USOTC
BASFY
BASF (QX)
CCOM
US100
US Tech 100
USOTC
RHHBY
Roche (QX)
CCOM
US500
US 500
USOTC
BNPQY
BNP Paribas (QX)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten